Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutroganics files with OTC markets to remove stop sign
David Sackler, Nutroganics’ President & CEO, said, "We are pleased to announce this first step in increasing the disclosure and transparency of the operations and performance of Nutroganics
David Sackler, Nutroganics’ President & CEO, said, "We are pleased to announce this first step in increasing the disclosure and transparency of the operations and performance of Nutroganics
The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company’s key technology platform, its method for 3-dimensional expansion of placental
OncoMed has been informed by the participating clinical sites of recent on-target mild-to-moderate bone-related adverse events for the two programs. To date, bone-related adverse events have been observed
The registry is part of Merck’s new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. The research initiative and the new
Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association (EHA) meeting being held in Milan, Italy. The poster presentation includes data
The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help
This result represents the largest settlement of a pharmaceutical case ever for several of the involved states, and a much higher settlement for each individual state than what
NUVISAN is a fully integrated contract research organization providing clinical development and lab services to the global pharmaceutical industry. For over 30 years, NUVISAN has been assisting their
Ferrer, a privately-help Spanish pharmaceutical company, licensed US rights for Ozenoxacin to Medimetriks earlier this year. The multicenter, randomized, double-blinded, clinical study compares Ozenoxacin 1% cream versus placebo.
The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the ‘277 patent includes